Activation of PPARβ/δ-AMPK pathway shown to slow liver fibrosis development

A study led by Manuel Vázquez Carrera, group leader at the Diabetes and Associated Metabolic Diseases Networking Biomedical Research Centre (CIBERDEM) at the University of Barcelona, reveals advances in the understanding and treatment of liver fibrosis, a serious complication in the context of metabolic fatty liver disease, also known as MASLD (metabolic dysfunction-associated steatotic liver disease).

Calorie labels cut intake slightly, but alcohol impact unclear

Calorie labels on food may lower calorie intake, but findings on alcohol are inconclusive, indicating a gap in research for effective public health strategies.

January 21, 2025

FDA approves Bristol Myers and Karuna’s schizophrenia drug, in milestone for psychiatry

The FDA on Thursday approved Bristol Myers Squibb’s new schizophrenia drug in one of the year’s most anticipated regulatory decisions. The approval gives Bristol Myers

September 27, 2024

Hong Kong SPAC nixes diagnostics merger; Clay Siegall will run a public biotech again

HH&L Acquisition Co., a SPAC that went through a $360 million IPO in early 2021, has reneged on its business combination agreement. The Hong Kong-based

July 4, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.